Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fiber fix? study tests if a simple supplement boosts arthritis Drug's power

NCT ID NCT05812157

Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding a daily fiber supplement (inulin) to standard anti-IL-17 therapy could improve gut bacteria balance and treatment response in 76 adults with axial spondyloarthritis. Participants took either fiber or a placebo powder for three months. The main goal was to see if fiber increased beneficial gut bacteria. If successful, this simple addition might help patients get more out of their medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
inulin (Fibruline) fiber supplement
What this could lead to
If it works, this could point toward a simple dietary addition that helps people with axial spondyloarthritis respond better to their anti-IL-17 medication.
What could go wrong
This is a small, early-stage study focused on gut bacteria changes, not direct symptom improvement. The fiber supplement may not meaningfully affect disease activity or treatment outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

76 people

The number who actually took part.

Started

Oct 2023

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Patients with spondyloarthritis meeting the ASAS criteria * Patient considered by the treating rheumatologist for anti-IL-17 biomedication * Patients aged between 18 and 90 years of age * Patients who are affiliated to a French social security system or beneficiaries of such a system * Patients with no desire to become pregnant during the study period (Effective contraception for women of childbearing age during the study period (surgical sterilization, hormonal contraceptives, barrier method, intrauterine device)) Exclusion Criteria: * Lack of written informed consent after a time of reflection * Patients participating in other therapeutic research or having participated in research for which the exclusion period has not ended * Patient under court protection, guardianship or curatorship. * Patient unable to give consent. * Pregnant or breastfeeding woman * Patients with digestive disorders for which a chronic inflammatory bowel disease has not been excluded * Patients with fructose intolerance or glucose or galactose malabsorption * Patients with known intolerance to inulin or maltodextrin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Axial spondyloarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Axial Spondyloarthritis Dysbiosis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Axial spondyloarthritis

Contacts and locations

Locations

  • Montpellier University Hospital

    Montpellier, Hérault, 34000, France

  • Nîmes University Hospital

    Nîmes, Gard, 30029, France

  • Tours Regional University Hospital (Bretonneau)

    Tours, Indre-et-Loire, 37032, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.